FierceHealthcareFierceHealthITFierceHealthFinanceFierceEMRHospital ImpactFierceMobileHealthcare   FiercePharma

WellPoint's earnings drop, but investors pleased; FDA recommends genetic testing before AIDS drugs;

Tools
Tags
WellPoint
smoking
New England Journal of Medicine
Food and Drug Administration (FDA)
cholesterol-fighting drug
Bill Gates
Abacavir

> Though WellPoint Inc.'s earnings dropped 10 percent in the second quarter, investors seem pleased that the company is improving on previous mistakes of inaccurate medical cost assessments and missing earnings projections. Article

> According to a study in the New England Journal of Medicine, researchers in the U.K. found a genetic variant that causes myopathy--a muscle weakness--in patients taking cholesterol-lowering statins. Article

> The FDA is recommending genetic testing before doctors prescribe an AIDS medication called Abacavir--sold as Ziagen--as part of the personalized medicine movement, which seeks to find a suitable drug match for individual patients. Researchers say the screening would help cut down on negative reactions. Article

> Bill Gates and New York City Mayor Michael Bloomberg have teamed up to donate $500 million to prevent smoking and deaths related to smoking around the world. Article

And Finally... Talula Does The Hula From Hawaii--a first name? Article

Bookmark and Share
Get Your FREE FierceHealthcare Email Newsletter:
Be the first to comment

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.